

# CITATION REPORT

List of articles citing

Intracavernous alprostadil alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra)

DOI: 10.1016/s0090-4295(99)00612-3  
Urology, 2000, 55, 477-80.

**Source:** <https://exaly.com/paper-pdf/32091340/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
76	Current World Literature. <i>Current Opinion in Urology</i> , <b>2000</b> , 10, 655-682	2.8	
75	Andrology. <i>Current Opinion in Urology</i> , <b>2000</b> , 10, 611-2	2.8	
74	Current Awareness. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2000</b> , 9, 441-456	2.6	
73	Sildenafil citrate: a therapeutic update. <i>Clinical Therapeutics</i> , <b>2001</b> , 23, 2-23	3.5	65
72	Neurologic erectile dysfunction. <i>Urologic Clinics of North America</i> , <b>2001</b> , 28, 289-308	2.9	54
71	Neurogenic erectile dysfunction. <i>Clinical Autonomic Research</i> , <b>2001</b> , 11, 285-94	4.3	13
70	Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate. <i>International Journal of Impotence Research</i> , <b>2002</b> , 14, 38-43	2.3	34
69	Pharmacological aspects of erectile dysfunction. <i>The Japanese Journal of Pharmacology</i> , <b>2002</b> , 89, 101-12		14
68	Intracavernous injection as an option for aging men with erectile dysfunction. <i>Aging Male</i> , <b>2002</b> , 5, 177-180		
67	Topical alprostadil cream for the treatment of erectile dysfunction: a combined analysis of the phase II program. <i>Urology</i> , <b>2002</b> , 60, 1077-82	1.6	18
66	The ageing male and erectile dysfunction. <i>World Journal of Urology</i> , <b>2002</b> , 20, 28-35	4	8
65	Erectile dysfunction in the 21st century: whom we can treat, whom we cannot treat and patient education. <i>International Journal of Impotence Research</i> , <b>2002</b> , 14 Suppl 1, S29-34	2.3	21
64	Current status of local penile therapy. <i>International Journal of Impotence Research</i> , <b>2002</b> , 14 Suppl 1, S70-81	2.3	37
63	Acceptance, efficacy and preference of Sildenafil in patients on long term auto-intracavernosal therapy: a study with follow-up at one year. <i>International Journal of Impotence Research</i> , <b>2002</b> , 14, 483-6	2.3	4
62	High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction. <i>International Journal of Impotence Research</i> , <b>2002</b> , 14, 533-8	2.3	48
61	Pharmacological management of erectile dysfunction. <i>BJU International</i> , <b>2003</b> , 91, 446-54	5.6	74
60	The ageing male and erectile dysfunction. <i>BJU International</i> , <b>2003</b> , 92, 516-20	5.6	20

59	The efficacy and safety of a topical alprostadil cream, Alprox-TD, for the treatment of erectile dysfunction: two phase 2 studies in mild-to-moderate and severe ED. <i>International Journal of Impotence Research</i> , <b>2003</b> , 15, 10-7	2.3	31
58	Treatment satisfaction in patients with erectile dysfunction switching from prostaglandin E(1) intracavernosal injection therapy to oral sildenafil citrate. <i>International Journal of Impotence Research</i> , <b>2003</b> , 15, 444-9	2.3	17
57	Viability and safety of combination drug therapies for erectile dysfunction. <i>Journal of Urology</i> , <b>2003</b> , 170, S20-3; discussion S23	2.5	23
56	Erectile dysfunction. <i>Annual Review of Medicine</i> , <b>2003</b> , 54, 153-68	17.4	66
55	Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up. <i>Urology</i> , <b>2003</b> , 62, 110-5	1.6	90
54	Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. <i>Clinical Therapeutics</i> , <b>2003</b> , 25, 2724-37	3.5	66
53	Therapies for neurologic erectile dysfunction. <i>Expert Review of Neurotherapeutics</i> , <b>2003</b> , 3, 641-8	4.3	
52	Recent advances in the treatment of erectile dysfunction in patients with diabetes mellitus. <i>Endocrine Practice</i> , <b>2003</b> , 9, 52-63	3.2	10
51	Perspectives and Clinical Significance of Eicosanoids in Obstetric and Gynaecological Practice. 507-515		
50	Male and Female Sexual Dysfunction: Epidemiology, Pathophysiology, Classifications, and Treatment. <b>2004</b> , 573-585		0
49	Cyclodextrin-based pharmaceuticals: past, present and future. <i>Nature Reviews Drug Discovery</i> , <b>2004</b> , 3, 1023-35	64.1	1386
48	Treatment program for erectile dysfunction in patients with cardiovascular diseases. <i>American Journal of Cardiology</i> , <b>2004</b> , 93, 689-93	3	11
47	Intracavernous pharmacotherapy for erectile dysfunction. <i>Endocrine</i> , <b>2004</b> , 23, 149-55		28
46	Treatment Options for Erectile Dysfunction in Patients Failing Oral Drug Therapy. <i>EAU Update Series</i> , <b>2004</b> , 2, 75-83		11
45	A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1. <i>International Journal of Impotence Research</i> , <b>2005</b> , 17, 346-53	2.3	30
44	Intracavernous, Transurethral, and Topical Therapies for Erectile Dysfunction in the Era of Oral Pharmacotherapy. <b>2005</b> , 253-277		1
43	Clinical monograph for drug formulary review: erectile dysfunction agents. <i>Journal of Managed Care Pharmacy</i> , <b>2005</b> , 11, 151-71		34
42	Clinical and duplex US assessment of effects of sildenafil on cavernosal arteries of the penis: comparison with intracavernosal injection of vasoactive agents--initial experience. <i>Radiology</i> , <b>2005</b> , 237, 986-91	20.5	16

41	An outbreak of Phialemonium infective endocarditis linked to intracavernous penile injections for the treatment of impotence. <i>Clinical Infectious Diseases</i> , <b>2005</b> , 40, 781-6	11.6	31
40	Oral Pharmacotherapy for Male Sexual Dysfunction. <b>2005</b> ,		
39	A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?. <i>Drugs</i> , <b>2005</b> , 65, 1621-50	12.1	133
38	Treatment for erectile dysfunction based on patient-reported outcomes: to every man the PDE5 inhibitor that he finds superior. <i>Drugs</i> , <b>2005</b> , 65, 2245-51	12.1	24
37	Erectile dysfunction following radical retropubic prostatectomy: epidemiology, pathophysiology and pharmacological management. <i>Drugs and Aging</i> , <b>2006</b> , 23, 101-17	4.7	37
36	An overview of the diagnosis and treatment of erectile dysfunction. <i>Drugs</i> , <b>2006</b> , 66, 2339-55	12.1	17
35	Contemporary intracavernous pharmacotherapy for erectile dysfunction in the aging male. <i>Aging Health</i> , <b>2006</b> , 2, 559-570		2
34	Management of sildenafil treatment failures. <i>Current Opinion in Urology</i> , <b>2006</b> , 16, 449-59	2.8	33
33	Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. <i>Journal of Sexual Medicine</i> , <b>2006</b> , 3, 901-909	1.1	45
32	Treating erectile dysfunction when PDE5 inhibitors fail. <i>BMJ, The</i> , <b>2006</b> , 332, 589-92	5.9	82
31	The substitution of Phentolamine with an equal amount of Chlopromazine as an alpha-blocker in vasoactive cocktails used for intracavernous injection therapy for the treatment of erectile dysfunction. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , <b>2007</b> , 49, 14-14b	0.6	
30	Salvage strategies for nonresponders to phosphodiesterase-5 inhibitor treatment for erectile dysfunction in the aging male. <i>Aging Health</i> , <b>2007</b> , 3, 527-542		1
29	Different hemodynamic responses by color Doppler ultrasonography studies between sildenafil non-responders and responders. <i>Asian Journal of Andrology</i> , <b>2007</b> , 9, 129-33	2.8	13
28	Vacuum erection devices to treat erectile dysfunction and early penile rehabilitation following radical prostatectomy. <i>Current Urology Reports</i> , <b>2008</b> , 9, 506-13	2.9	18
27	Intracavernosal injections and fibrosis: myth or reality?. <i>BJU International</i> , <b>2008</b> , 102, 525-6	5.6	12
26	Toward a new EPOCHV optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>International Journal of Clinical Practice</i> , <b>2009</b> , 63, 1214-30	2.9	17
25	Pharmacotherapy for erectile dysfunction. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 524-40	1.1	132
24	Vacuum erection devices revisited: its emerging role in the treatment of erectile dysfunction and early penile rehabilitation following prostate cancer therapy. <i>Journal of Sexual Medicine</i> , <b>2012</b> , 9, 1182-9 <sup>1.1</sup>		34

23	Angiotensin II increases corpus cavernosal contractility and oxidative stress in partial bladder outlet obstructed rabbits: relevance to erectile dysfunction. <i>Journal of Sexual Medicine</i> , <b>2013</b> , 10, 1251-8	1.1	3
22	Pharmacogenetics of erectile dysfunction: navigating into uncharted waters. <i>Pharmacogenomics</i> , <b>2014</b> , 15, 1519-38	2.6	20
21	Intracavernosal Injection for the Diagnosis, Evaluation, and Treatment of Erectile Dysfunction: A Review. <i>Sexual Medicine Reviews</i> , <b>2015</b> , 3, 11-23	5.6	30
20	Clinical use of alprostadil topical cream in patients with erectile dysfunction: a review. <i>Research and Reports in Urology</i> , <b>2016</b> , 8, 123-31	1.3	11
19	Erectile function after treatment for rhabdomyosarcoma of prostate and bladder. <i>Journal of Pediatric Urology</i> , <b>2016</b> , 12, 404.e1-404.e6	1.5	6
18	Contemporary Treatment of Erectile Dysfunction. <i>Contemporary Endocrinology</i> , <b>2016</b> ,	0.3	2
17	Delivery of intracavernosal therapies using needle-free injection devices. <i>International Journal of Impotence Research</i> , <b>2017</b> , 29, 225-228	2.3	5
16	Topical alprostadil (Vitaros) in the treatment of erectile dysfunction after non-nerve-sparing robot-assisted radical prostatectomy. <i>Urologia</i> , <b>2018</b> , 85, 55-59	1.2	3
15	Erectile Dysfunction. <i>Physician Assistant Clinics</i> , <b>2018</b> , 3, 113-127	0.2	0
14	Drug Complexation: Implications in Drug Solubilization and Oral Bioavailability Enhancement. <b>2018</b> , 473-512		3
13	Erectile dysfunction management after failed phosphodiesterase-5-inhibitor trial: a cost-effectiveness analysis. <i>Translational Andrology and Urology</i> , <b>2019</b> , 8, 387-394	2.3	6
12	A Review of Economic Evaluations of Erectile Dysfunction Therapies. <i>Sexual Medicine Reviews</i> , <b>2020</b> , 8, 497-503	5.6	7
11	Treatment of Erectile Dysfunction. <b>2006</b> , 284-290		1
10	Erectile Dysfunction: Pharmacological Therapy. <b>2011</b> , 675-696		1
9	Self-Injection, Transurethral, and Topical Therapy in Erectile Dysfunction. <b>2016</b> , 187-207		1
8	Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence. <i>Clinical Interventions in Aging</i> , <b>2006</b> , 1, 403-14	4	36
7	Diagnosis and Therapy of Erectile Dysfunction Following Radical Prostatectomy. <b>2003</b> , 211-220		
6	MUSE and Intracavernosal Therapies. <b>2004</b> , 121-128		

- 5 Self-Injection, Transurethral and Topical Therapy in Erectile Dysfunction. **2011**, 107-125
- 4 Difference of opinion - Is There a Space to Improve the Treatment of Erectile Dysfunction in the Next Years? Opinion: YES. *International Braz J Urol: Official Journal of the Brazilian Society of Urology*, **2015**, 41, 830-1 2
- 3 Erectile dysfunction: drug treatment. *Revista Da Associação Médica Brasileira*, **2019**, 65, 1133-1142 1.4 1
- 2 Oral pharmacotherapy and the contemporary evaluation and management of erectile dysfunction. *Reviews in Urology*, **2003**, 5 Suppl 7, S9-S20 1 1
- 1 Treatment of Erectile Dysfunction. **2006**, 284-290